Search for a trial

Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinoma

Primary:To evaluate if progression-free survival from randomization to progression or death during second-line therapy (total PFS) of sorafenib followed by pazopanib is non-inferior compared to pazopanib followed by sorafenib.Secondary:1. Time from…

Validation of a strategy to identify benign pathology in patients operated for a complex renal cyst. (RECIST: REnal Cysts: Indications for Surgery Trial)

To validate a diagnostic panel existing of MRI, CEUS, and FNA, which can differentiate benign pathology from malignant pathology of complex renal cysts.

Phase II study of sunitinib rechallenge in patients with metastatic renal
cell carcinoma.

To determine whether sunitinib rechallenge in patients with mRCC, who had benefit from prior treatment with sunitinib and who progressed on both sunitinib and second-line therapy (or a period of more than 3 months without treatment), can again…

Quantification of Contrast Enhanced Ultrasound (CEUS) in the detection of Prostate cancer.

2.1 Primary objective: To improve PCa detection rate with quantification, compared with subjective CEUS interpretation and known numbers in literature. 2.2 Secondary objective: To compare quantification results with tumour differentiation grade (…

Effects of dosing time on the pharmacokinetics and pharmacodynamics of sunitinib.

Primairy objective:To investigate whether the pharmacokinetics of sunitinib are influenced by circadian rhythm.Secondary objective:- to investigate whether daily variation in CYP3A4 activity exists in humans, based on midazolam and 4beta-…

Detecting prostate cancer by the intracellular presence of prostate-specific antigen in macrophages, detected in peripheral blood samples by a flow cytometric technique.

At the Atrium Medical Center Heerlen, in 2005 a study has been initiated with the aim of developing a new diagnostic tool for patients with prostate carcinoma. By using flow cytometry, PSA can be measured in activated monocytes, naming macrophages.…

Prediction of response to kinase inhibitors based on protein phosphorylation profiles in tumor tissue from advanced renal cell cancer patients

To determine the relation between tumor tissue phosphoproteomic profiles and progression-free survival (PFS) in patients with advanced RCC

BONE MINERAL DENSITY IN PROSTATE CANCER PATIENTS TREATED WITH ANDROGEN DEPRIVATION THERAPY

To assess whether a change in BMD as detected big DXA (gold standard) is comparable with the decline measured by the achilles method